In the long arc of medicine's relationship with the mind, a compound once confined to counterculture and controversy has now cleared its second major late-stage clinical trial. Definium Therapeutics announced that DT120 ODT, an orally dissolving form of LSD, met its primary endpoints in the Phase 3 Panorama study for generalized anxiety disorder — a condition that quietly diminishes the lives of millions. This second victory is not merely a corporate milestone; it is a signal that the boundary between fringe and frontier is dissolving, and that suffering, given enough time and evidence, tends